Business Context and Reporting Period
This Form 8-K filing by Prelude Therapeutics Inc. (PRLD) covers events occurring on January 22, 2021, with a report date of January 28, 2021. The filing addresses Item 5.02 regarding the departure of a director and the appointment of a new director to the Board.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
- Director Resignation: Dr. Kelvin Neu resigned from the Board and all committees, effective January 25, 2021. The resignation was not due to any disagreement with the Company regarding operations, policies, or practices.
- Director Appointment: Julian C. Baker was appointed to fill the vacancy as a Class II Director, effective January 25, 2021. His term expires at the 2022 Annual Meeting.
- Committee Roles: Mr. Baker will serve on the Compensation Committee and act as Chairman of the Nominating and Governance Committee.
- Independence: The Board determined Mr. Baker qualifies as an independent director under the Securities Exchange Act of 1934 and Nasdaq listing standards.
Guidance, Outlook, and Compensation
The filing contains no guidance, outlook, or management commentary regarding business operations or risks. However, it details the compensatory arrangements for the new director:
- Equity Grant: Mr. Baker is entitled to an annual stock option grant for 23,344 shares of voting common stock at the fair market value on the grant date. This grant vests one year after the grant date or at the next annual meeting, assuming continued service.
- Cash Retainer: Mr. Baker is entitled to the applicable annual cash retainer for non-employee directors.
- Affiliate Ownership: As a Managing Member of Baker Bros. Advisors LP, Mr. Baker may be deemed to have beneficial ownership of securities held by affiliated entities. These entities hold more than 5% of the Company's outstanding voting and non-voting common stock and are parties to investor and registration rights agreements.
Investor Verification Checklist
- Verify the effective date of Dr. Neu's resignation and Mr. Baker's appointment (January 25, 2021).
- Confirm the specific number of shares in the annual stock option grant (23,344 shares) and the vesting schedule.
- Review the beneficial ownership disclosures regarding Baker Bros. Advisors LP and their >5% stake in the Company.
- Check the Company's 2020 Equity Incentive Plan for details on the option grant terms and change of control acceleration provisions.